ALT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AL

Mkt Cap

$427.0M

Volume

3.76M

Next Earnings

November 5th

Loading chart

AL

ALTAltimmune, Inc. Common Stock

ALT

Pay with—

Available Balance0.00

AL

Mkt Cap

$459.1M

Volume

3.76M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating.Zacks Investment Research · Oct 7, 2026

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?Altimmune reported a Q2 2026 loss of 12 cents per share, beating the consensus estimate of 15 cents, with no revenues as the company lacks marketed drugs. R&D expenses rose 8.2% to $18.7 million, primarily due to ongoing MASH clinical studies. The company's cash position strengthened to $519 million, supporting operations into 2029. Shares have gained 14.2% over the past month, outperforming the S&P 500, though the stock carries a Zacks Rank #3 (Hold) rating with an overall VGM Score of F.Zacks Investment Research · Sep 11, 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightThe alcohol use disorder (AUD) market is projected to grow at a 12.1% CAGR from 2026-2036, driven by novel therapeutic mechanisms and new drug approvals. The market was valued at USD 1.1 billion in 2025 across seven major markets. Key emerging therapies from companies like Adial Pharmaceuticals, Eli Lilly, MediciNova, and Altimmune are expected to transform the treatment landscape, with AD04 projected to capture the largest market share by 2036, replacing current leader VIVITROL.GlobeNewswire Inc. · Jun 8, 2026

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026Altimmune announced 48-week data from its IMPACT Phase 2b trial showing that pemvidutide, a glucagon/GLP-1 dual receptor agonist, significantly reduced triglycerides (-23.7%), total cholesterol (-15.4%), and improved weight loss (7.5%), blood pressure, and waist circumference in MASH patients. The drug demonstrated a favorable safety profile with minimal discontinuations due to adverse events. The company plans to initiate the PERFORMA Phase 3 trial in the second half of 2026.GlobeNewswire Inc. · May 28, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of SecuritiesAltimmune closed a $225 million oversubscribed public offering led by Deep Track Capital, with participation from TCGX, Viking Global Investors, and RA Capital Management. The company will use proceeds to fund its Phase 3 MASH trial expected to initiate in H2 2026 and provide cash runway through the anticipated 52-week data readout. Pemvidutide, Altimmune's dual-action therapy targeting glucagon and GLP-1 receptors, is being developed for MASH, alcohol use disorder, and alcohol-associated liver disease.Benzinga · Apr 27, 2026

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesAltimmune, Inc. (Nasdaq: ALT) announced the pricing of an underwritten public offering of common stock and warrants expected to raise approximately $225 million in gross proceeds. The offering consists of 64.25 million shares of common stock with accompanying warrants at $3.00 per share, plus optional pre-funded warrants. The company plans to use net proceeds to fund its Phase 3 MASH trial and general corporate purposes. The offering is expected to close on April 24, 2026.GlobeNewswire Inc. · Apr 23, 2026

Anti-Aging Protein Research Takes a Step Forward with Cell CloningAvaí Bio announced a critical milestone in creating a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, an anti-aging protein that declines by 50% after age 40. The company is partnering with Austrianova to use Cell-in-a-Box encapsulation technology for its Klothonova anti-aging and Insulinova diabetes programs. This development occurs as the cell and gene therapy market expands rapidly, with the sector forecast to grow from $10.4 billion to over $45 billion by 2035.Benzinga · Mar 24, 2026

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common StockAltimmune Inc (NASDAQ: ALT) closed a $75 million registered direct offering of common stock, issuing 17,045,454 shares to a new fundamental institutional investor. The company plans to use the net proceeds for its Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and general corporate purposes. The offering strengthens Altimmune's balance sheet as it advances its lead candidate pemvidutide, a dual glucagon/GLP-1 agonist that received FDA Breakthrough Therapy Designation.Benzinga · Jan 29, 2026

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common StockAltimmune, Inc. closed a $75 million registered direct offering of common stock and pre-funded warrants to strengthen its balance sheet. The company plans to use proceeds for its Phase 3 trial of pemvidutide, a dual glucagon/GLP-1 agonist for MASH treatment, which recently received FDA Breakthrough Therapy Designation.GlobeNewswire Inc. · Jan 29, 2026

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationThe healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.Benzinga · Jan 29, 2026

to start trading

AL

ALTAltimmune, Inc. Common Stock

ALT

Pay with—

Available Balance0.00

Your PositionYou don't own any ALT yet.

Related Tickers

Earnings